Company Registration No. 12450812 (England and Wales)
Bioactive Pharma Ltd
Unaudited accounts
for the year ended 31 December 2024
Bioactive Pharma Ltd
Unaudited accounts
Contents
Bioactive Pharma Ltd
Company Information
for the year ended 31 December 2024
Director
K L Aspinall Nessling
Company Number
12450812 (England and Wales)
Registered Office
14 Whyke Road
Chichester
PO19 7AN
England
Bioactive Pharma Ltd
Statement of financial position
as at 31 December 2024
Tangible assets
3,874
5,922
Investments
833,309
566,277
Cash at bank and in hand
18,057
26,334
Creditors: amounts falling due within one year
(240,790)
(76,539)
Net current assets
5,747
269,234
Net assets
842,930
841,433
Called up share capital
97
97
Share premium
1,044,974
1,044,974
Profit and loss account
(202,141)
(203,638)
Shareholders' funds
842,930
841,433
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 26 September 2025 and were signed on its behalf by
K L Aspinall Nessling
Director
Company Registration No. 12450812
Bioactive Pharma Ltd
Notes to the Accounts
for the year ended 31 December 2024
Bioactive Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 12450812. The registered office is 14 Whyke Road, Chichester, PO19 7AN, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Preparation of consolidated financial statements
The financial statements contain information about Bioactive Pharma Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.
Revenue, described as turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes
The company operates a defined contribution scheme. Contributions payable are recognised in the profit and loss account when due.
Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
Straight line over 3 years
Computer equipment
Straight line over 3 years
Bioactive Pharma Ltd
Notes to the Accounts
for the year ended 31 December 2024
4
Tangible fixed assets
Plant & machinery
Computer equipment
Total
Cost or valuation
At cost
At cost
At 1 January 2024
300
9,478
9,778
At 31 December 2024
300
11,267
11,567
At 1 January 2024
198
3,658
3,856
Charge for the year
102
3,735
3,837
At 31 December 2024
300
7,393
7,693
At 31 December 2024
-
3,874
3,874
At 31 December 2023
102
5,820
5,922
5
Investments
Subsidiary undertakings
Valuation at 1 January 2024
566,277
Valuation at 31 December 2024
833,309
Amounts falling due within one year
Trade debtors
132,533
291,475
Accrued income and prepayments
95,722
27,962
7
Creditors: amounts falling due within one year
2024
2023
Trade creditors
29,576
47,846
Amounts owed to group undertakings and other participating interests
217,134
-
Taxes and social security
15,653
26,400
Loans from directors
(24,911)
109
8
Transactions with related parties
Interest is being charged on the overdrawn director's loan included within creditors.
Bioactive Pharma Ltd
Notes to the Accounts
for the year ended 31 December 2024
9
Average number of employees
During the year the average number of employees was 5 (2023: 4).